Flamel Technologies Announces Fourth Quarter and Year-End 2009 Results
08.03.10
Today announced its financial
results for the fourth quarter and year ended December 31, 2009.
Fourth Quarter Highlights:
--
Pfizer exercised the option to license the Medusa platform for
development of an improved intravenous formulation of an
already-marketed molecule acquired in its merger with Wyeth;
--
The Company signed new feasibility studies applying the Medusa
platform to three new molecules with two top-ten pharmaceutical
companies;
--
The Company announced that the Agence Nationale de Recherche sur le
SIDA et les Hepatites Virales (ANRS) initiated a twelve week study
comparing two dosage forms of IFN-alpha XL plus ribavirin versus
Peg-Intron(R) plus ribavirin in genotype 1 Hepatitis C patients.
Stephen H. Willard, Flamel's chief executive officer, stated, "Flamel
continued to expand its portfolio of projects with leading
pharmaceutical companies during the fourth quarter We are now working
with eight of the top twenty-five pharmaceutical companies in the world.
We have progressed in the projects undertaken over the past two years,
and expect that these projects will be the subject of increased
communication during the coming year."
Source: MarketWatch (press release)
PEOPLE'S PHARMACY Surprising remedy for nosebleeds
28.02.10
Q: A wrestling coach taught me a procedure to stop nosebleeds. Determine which nostril is bleeding, remove the shoe from the opposite foot and, with the heel of your hand, give two good thumps to the heel of that bare foot. Why does this work?
A: We wish we could tell you. Many readers have shared success stories with that technique. Even though we can't explain either approach, it will be obvious within seconds whether it has worked.Drugstore alternatives include Nosebleed QR, NasalCEASE and Seal-On.
Q: My mother has type 2 diabetes and has had a terrible time getting her blood sugar under control even though she takes metformin and Actos. I suspect that the risperidone she takes for her nerves and the Lipitor for lowering cholesterol might be making this harder. Are there any natural approaches that might help her keep her blood sugar and cholesterol under control?
Source: Houston Chronicle
Flamel Technologies Announces Projected Release Date of Fourth Quarter and ...
01.03.10
Expects to release its financial
results for the fourth quarter and the fiscal year 2009 on Monday,
March 8th, after the market close. A conference call to discuss the
results has been scheduled for Tuesday March 9th, at 8:30 AM (EST). A
question and answer period is expected to follow management's
prepared remarks.
To participate in the conference call, investors in the US and Canada
are invited to dial 1-877-857-6173. International callers are invited
to call 1-719-325-4888. The Conference ID number is: 2453008. The
conference call webcast may be accessed at www.flamel.com .
Flamel Technologies, S.A. is a biopharmaceutical company principally
engaged in the development of two unique polymer-based delivery
technologies for medical applications. Micropump(R) is a controlled
release technology for the oral administration of small molecule
drugs; it is the intellectual property platform licensed by
GlaxoSmithKline for the development of Coreg CR(TM). Flamel's
Medusa(R) technology is designed to deliver controlled-release
formulations of therapeutic proteins and peptides.
Source: MarketWatch (press release)
